PathWhiz

Pathway Description

Nadroparin Action Pathway

Homo sapiens

Drug Action Pathway

Nadroparin is a heparin with a low molecular weight, with the brand name Fraxiparine. Its mechanism of action after subcutaneous administration causes it to bind to antithrombin III and inactive factor Xa. The inactivation of factor Xa halted the conversion of prothrombin to thrombin and also halts the conversion of fibrinogen. This inhibits the coagulation cascade, afterwards, Nadroparin is metabolized in the liver. Later it is eliminated through the kidneys, too much nadroparin can cause osteopenia, skin necrosis, thrombocytosis, thrombocytopenia, eosinophilia, calcinosis and severe bleeding.

References

Nadroparin Pathway References

Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995 Apr;73(4):630-40.

Pubmed: 7495071

Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. doi: 10.1159/000217270.

Pubmed: 8707165

Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, Yu AW: Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis. 1996 Nov;28(5):721-6. doi: 10.1016/s0272-6386(96)90254-1.

Pubmed: 9158210

Highlighted elements will appear in red.

Highlight Compounds

	Calcium
	Nadroparin

Highlight Proteins

	Antithrombin-III
	Coagulation factor X
	Fibrinogen alpha chain
	Fibrinogen beta chain
	Fibrinogen gamma chain
	Thrombin

Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.

Visualize Compound Data